Propionic Acidemia Market Share

North American Market Forecasts

The propionic acidemia market in the North America region is set to hold the highest CAGR of 35% by the end of 2036. This growth can be attributed to improved healthcare infrastructure, FDA approvals, increased prevalence of propionic acidemia, collaboration and acquisitions with key players and others expected to dominate this region during the forecast period. For example, an orphan drug designation for AAV9hPCCA for the treatment of propionic acidemia was granted by the FDA to the National Center for Advancing Translational Sciences in May 2022.

APAC Market Statistics

The propionic acidemia market in the Asia Pacific region is set to grow significantly during the time period between 2024-2036. Newborn screening programs are essential for early diagnosis of propionic acidemia, as early intervention can significantly enhance patient outcomes. The adoption of newborn screening programs is increasing in the Asia Pacific region, which is anticipated to lead toa rise in diagnosed cases of propionic acidemia and consequently the propionic acidemia market.

Frequently Asked Questions (FAQ)

The growing awareness about propionic acidemia and increasing prevalence of propionic acidemia are some of the major factors anticipated to drive the growth of the propionic acidemia market.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2024 - 2036.

The major players in the market are of China Biologic Products Holdings Inc., Teva Pharmaceuticals, Wellona Pharma, Merck, AdvaCare Pharma, and others.

The L-carnitine segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Propionic Acidemia Market Share